Minimal residual disease as a potential surrogate end point—lingering questions
A partir d'une revue systématique de la littérature publiée entre 1990 et 2016 (26 études incluant au total 2 373 cas), cette méta-analyse met en évidence une association entre l'absence, après traitement, d'une maladie résiduelle minimale et l'amélioration de la survie chez les patients atteints d'un myélome multiple
In the treatment of multiple myeloma (MM), there have been important advances in recent decades. The introduction of new therapeutics, the use of high-dose therapy, and better supportive care have translated into longer progression-free survival (PFS), overall survival (OS) times, and higher response rates.1 For example, in a recent phase 3 randomized trial2 evaluating lenalidomide and dexamethasone with or without daratumumab, the reported overall response rate was 93%. Given these improvements, there has been interest in the development of surrogate end points to expedite drug development.
JAMA Oncology , éditorial en libre accès, 2015